HRT FINANCIAL LP sold $73K of CMND

HRT FINANCIAL LP sold 22,139 shares of Clearmind Medicine Inc. (CMND) at $3.31 on 2026-06-16.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 18, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CMND
Bearish
medium confidence
Mentioned
$CMND
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBearishLow
01

Why it matters

A disclosed open-market sale by a 10% owner can influence microcap sentiment and short-term order flow, but it does not provide new operating, regulatory, or financial guidance.

02

Market read

Traders may treat this as a modest negative sentiment datapoint for CMND, mainly relevant for positioning around liquidity and ownership signals.

03

What to watch

The filing does not disclose intent; traders should watch for subsequent Form 4s from the same holder and compare total remaining ownership (81,353 shares after sale) versus prior filings.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBearishMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 showing an open-market sale of 22,139 CMND shares at $3.3060 on 2026-06-16.

Expected impact

Likely limited, short-lived sentiment pressure; any move would be small unless follow-on selling is disclosed.

Evidence & confidence

The filing is primary-source (Form 4) and quantifies the sale size and price, but it lacks a stated reason and is not a company operational update.

Market effects

No clear sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is not used here, but sales can be routine liquidity/portfolio rebalancing rather than a bearish view on the business.

Key entities

  • Clearmind Medicine Inc.

    Subject of the Form 4 insider transaction; ticker CMND.

  • HRT Financial LP

    Reporter/large holder executing the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.